El Badri, S;
Lord, S;
Harman, R;
McIntosh, D;
Mukherjee, S;
Ooms, A;
Parkes, M;
... Hawkins, MA; + view all
(2022)
CHARIOT trial (cohort A2): A phase I dose-escalation study combining the ATR inhibitor berzosertib with cisplatin and capecitabine.
Presented at: Annual Meeting of the European-Society-for-Medical-Oncology (ESMO).
Preview |
Text
CHARIOT_A2Abstract_ESMO2022_03May2022.pdf - Other Download (87kB) | Preview |
| Type: | Conference item (Presentation) |
|---|---|
| Title: | CHARIOT trial (cohort A2): A phase I dose-escalation study combining the ATR inhibitor berzosertib with cisplatin and capecitabine |
| Event: | Annual Meeting of the European-Society-for-Medical-Oncology (ESMO) |
| Dates: | 9 Sep 2022 - 13 Sep 2022 |
| Open access status: | An open access version is available from UCL Discovery |
| DOI: | 10.1016/j.annonc.2022.07.612 |
| Publisher version: | https://doi.org/10.1016/j.annonc.2022.07.612 |
| Language: | English |
| Additional information: | This version is the author accepted manuscript. For information on re-use, please refer to the publisher’s terms and conditions. |
| UCL classification: | UCL UCL > Provost and Vice Provost Offices > UCL BEAMS UCL > Provost and Vice Provost Offices > UCL BEAMS > Faculty of Engineering Science UCL > Provost and Vice Provost Offices > UCL BEAMS > Faculty of Engineering Science > Dept of Med Phys and Biomedical Eng |
| URI: | https://discovery.ucl.ac.uk/id/eprint/10162292 |
Loading...
Loading...Loading...| 1. |  United States | 1 |
| 2. |  France | 1 |
| 3. |  Japan | 1 |
| 4. |  Russian Federation | 1 |
| 5. |  United Kingdom | 1 |
Archive Staff Only
 |
View Item |
